Endovenously administered oncolytic viruses extravasate and penetrate poorly into tumors. iRGD is a cyclic peptide that enhances tumor penetration when conjugated or coadministered with different types of molecules such as drugs, nanoparticles or phages. iRGD-mediated tumor penetration occurs in three steps: binding to αv-integrins on tumor vasculature or tumor cells, exposure by proteolysis of a C-terminal motif that binds to neuropilin-1 (NRP-1) and cell internalization. We have genetically inserted the iRGD peptide in the fiber C terminus of ICOVIR15K, an oncolytic tumor-retargeted adenovirus to increase its tumor penetration. In vitro, NRP-1 interaction improved binding and internalization of the virus in different cancer cells overexpressing integrins and NRP-1. However, such NRP-1-mediated internalization did not affect transduction or cytotoxicity. In vivo, iRGD did not change the normal organ transduction pattern, with liver and spleen as main targeted organs. In tumors, however, iRGD enhanced transduction and early adenovirus dissemination through the tumor mass leading to an improved antitumor efficacy.
INTRODUCTION
Oncolytic adenoviruses hold promise as new agents for cancer therapy, but their efficacy in the clinic needs improvement. 1 Poor tumor targeting, 2, 3 and limited tumor penetration 4 upon systemic administration contribute to such inefficacy. Enhancing tumor blood vessel permeability and targeting viruses to tumor vasculature and tumor cells 5 are novel strategies to improve tumor targeting. Tumor vasculature presents two properties that can be exploited to deliver selectively drugs to tumors. First, the combined effect of a vascular leakiness and a poor lymphatic drainage induces a passive accumulation of macromolecules at the vascular rim of the tumor, known as enhanced permeability and retention effect (EPR effect). 4 However, the poor lymphatic drainage also leads to a high interstitial pressure that combined with the dense extracellular matrix of the tumor impairs extravasation and intratumoral diffusion of macromolecules. Second, certain angiogenic and inflammatory proteins such as integrins, vascular endothelial growth factor receptors and their coreceptors, such as neuropilin-1 (NRP-1), 6, 7 are overexpressed in the luminal side of the tumor vessels. These proteins have been used to target viruses to tumor vasculature. 8 However, an ideal oncolytic virus should not only enhance its binding to the blood vessels but also cross the vascular wall and penetrate into the tumor parenchyma against the high interstitial pressure.
The addition of high-affinity ligands has been used to redirect adenoviruses to tumor vessels and tumor cells. Probably, the most successfully identified ligand is the RGD-integrin-binding peptide, which has been inserted in different adenovirus capsid proteins. [9] [10] [11] [12] [13] [14] However, when a phage displaying this RGD peptide is administered systemically, it binds to tumor blood vessels but it cannot extravasate and penetrate into the tumor mass. 15 Seeking to improve adenovirus transport across endothelial cells and deep into the tumor parenchyma, we inserted the iRGD (CRGDKGPDC) peptide in the fiber C terminus of the oncolytic adenovirus ICOVIR15K. iRGD is a peptide with unique cell and tissuepenetrating properties identified by a phage display selection in vivo when screening for peptides that extravasate tumor blood vessels in a metastatic tumor model. 16 iRGD combines tumorhoming and NRP-1-dependent tissue-penetrating properties activated by proteolytic exposure of its C-terminal end, a property known as C-terminal rule or CendR. The RGD motif present in this peptide binds to αv-integrins overexpressed in the tumor endothelium. Then, an unknown tumor-associated protease cleaves the iRGD peptide exposing a CendR neuropilin-1-binding motif that mediates penetration into tumors leading to a widespread distribution of the peptide through the tumor mass. 16 Increased expression of NRP-1 correlates with tumor aggressiveness, stage and poor prognosis in several tumor types. [17] [18] [19] The iRGD peptide improves tumor imaging of iRGDconjugated nanoparticles and antitumor efficacy of iRGD-coated abraxane. 16 Moreover, iRGD coadministered with different drugs improves their antitumor activity.
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ICOVIR15K oncolytic adenovirus achieves tumor selectivity by the Δ24 deletion in its viral genome that abrogates E1A binding to pRb. In addition, four E2F binding sites and one Sp-1 binding site in the E1A endogenous promoter were incorporated to control E1A-Δ24 transcription upon pRb deregulation. 21 The KKTK heparan sulfate proteoglycan-binding domain of the ICOVIR15K fiber shaft was replaced by an RGDK motif that binds to integrins. This capsid modification improves tumor-to-liver ratio 20-fold compared with wild-type capsid, 11 conferring superior antitumor activity than the RGD insertion at the HI loop of the fiber knob after systemic administration in several tumor models. 22 We hypothesized that the iRGD peptide insertion could enhance adenovirus extravasation from blood vessels and penetration through the tumor mass even in the setting of an RGDK-modified oncolytic adenovirus.
RESULTS
Insertion of the iRGD peptide in the oncolytic adenovirus ICOVIR15K fiber C terminus increases binding and internalization of the virus into the cell To increase adenovirus penetration into the tumor parenchyma, the iRGD tumor-penetrating peptide was inserted in the ICOVIR15K fiber C terminus, generating the ICOVIR15K-iRGD oncolytic virus. As the C terminus points inwards toward the shaft, the flexible linker (GGGGS) 3 was added before the iRGD peptide to allow for a better processing of the iRGD peptide and facilitate its interaction with integrins and NRP-1. This linker has been used to construct scFv (single-chain variable fragments) and spans 35 Å between the C-and the N-terminus variable domains without distorting the conformation of the antigen binding site. 23 The rescue of functional ICOVIR15K-iRGD virus proved that the insertion of the linker and the iRGD peptide in the fiber C terminus allowed the proper fiber trimerization, which has been suggested to be more dependent on the peptide structure than on its size. 24 Binding and internalization of ICOVIR15K-iRGD were assessed in different cell lines. As a control for NRP-1 binding, the RPARPAR peptide, which is the NRP-1-binding CendR prototype peptide, 25 was also inserted in the ICOVIR15K fiber C terminus generating the ICOVIR15K-RPARPAR. We demonstrated that the interaction with NRP-1 through RPARPAR peptide improved binding and internalization into the cell when the levels of NRP-1 were high (in human umbilical vein endothelial cell (HUVEC) and A549 cells) and moderate (MCF7), but not when NRP-1 levels were low (MIA PaCa-2 cells) (Figures 1a and d and see Supplementary Figure S1b for NRP-1 immunofluorescence staining of these cells). To function as a CendR peptide, iRGD needs to bind to both integrins and NRP-1, and also to be processed by an unknown protease present in the tumor. 16 This mechanism confers tumor selectivity to the iRGD. We showed that in vitro, the iRGD peptide enhanced binding and internalization only in MCF7 cells, which express NRP-1 and integrins. In HUVEC and A549 cells, which display high levels of integrins and NRP-1, these effects were not observed probably owing to the lack of this putative protease or to the competition with the natural adenovirus primary receptors (Figures 1a and d and Supplementary Figure S1 ).
To check if the enhanced binding and internalization of these viruses into cancer cells led to enhanced transduction, adenoviral vectors expressing GFP (green fluorescent protein)-luciferase fusion protein (GL) with the KKTK-to-RGDK fiber modification and with (AdGLK-iRGD) or without (AdGLK) the iRGD peptide inserted in the fiber C terminus were also generated. iRGD insertion in the AdGLK adenoviral vector also increased the binding in MCF7 cells (data not shown), but this insertion did not change transduction in any of the cell lines tested (Figure 2a and Supplementary Figure S2 ). In addition, cytotoxicity dose-response experiments with ICOVIR15K-iRGD and ICOVIR15K-RPARPAR confirmed that the insertion of these peptides did not change virus cytotoxicity in A549 lung carcinoma ( Figure 2b ) and in MIA PaCa-2 pancreatic carcinoma cell lines ( Figure 2c ) compared with the control virus ICOVIR15K. Overall, these results indicate that iRGD insertion does not impair virus infection and replication.
Insertion of the iRGD peptide in the RGDK fiber C terminus increases tumor transduction, but it does not affect adenovirus transduction of other organs To determine if iRGD could increase tumor transduction in vivo, nude mice bearing subcutaneous MIA PaCa-2 pancreatic xenograft tumors were injected endovenously with phosphatebuffered saline (PBS) or 4 × 10 10 viral particles per mice (vp/mice) of AdGLK or AdGLK-iRGD. Liver and spleen were the main targeted organs and were similarly transduced by both vectors (Figure 3a) . Only in the tumor a significant differential transduction was noted, with a twofold advantage in favor of AdGLK-iRGD compared with AdGLK (P ⩽ 0.05) (quantitative data for tumors shown in Figure 3b and for liver in Figure 3c ). The tumor-to-liver ratio per animal increased threefold (P = 0.036) owing to the insertion of iRGD in the fiber C terminus (Figure 3d ).
Insertion of the iRGD peptide in the oncolytic adenovirus ICOVIR15K enhances early adenovirus dissemination through the tumor mass As a surrogate marker of enhanced penetration, we analyzed early adenovirus dissemination through the tumor mass. To this end, nude mice bearing subcutaneous A549 lung carcinoma xenograft tumors were systemically treated with PBS or 4 × 10 10 vp/mice of ICOVIR15K, ICOVIR15K-RPARPAR or ICOVIR15K-iRGD. The replication foci were analyzed at day 11 after virus administration when only a few rounds of virus replication had occurred. We considered this replication necessary to detect the virus in tumor sections. The E1A-positive area in ICOVIR15K-RPARPAR-and ICOVIR15K-iRGD-treated tumors increased almost six-and fourfold compared with ICOVIR15K-treated tumors (P = 0.017 and 0.00089, respectively) ( Figure 4a ) with an increase in the number and the size of the replication foci. No significant differences were found between the RPARPAR and the iRGD viruses as both peptides should enhance NRP-1-mediated vascular cross. Representative images of ICOVIR15K-iRGD are shown in Figure 4b where staining against α-smooth muscle actin (α-SMA), expressed in pericytes and fibroblasts, is shown in red and adenovirus E1A in green. Given the fact that the iRGD peptide did not enhance transduction and cytotoxicity of the virus in vitro in A549 cells (Figures 2a and b), we associated this enhanced dissemination to an improved virus penetration through the tumor mass after systemic delivery of the virus.
Insertion of the iRGD peptide in the oncolytic adenovirus ICOVIR15K enhances antitumor efficacy Finally, we studied the effect of iRGD insertion in terms of antitumor efficacy. To assess this, we compared the tumor volume after the treatment with ICOVIR15K or ICOVIR15K-iRGD in two different tumor models: an A549 lung adenocarcinoma tumor model expressing high NRP-1 levels and an MIA PaCa-2 pancreatic adenocarcinoma tumor model expressing low NRP-1 levels. Nude mice bearing either A549 or MIA PaCa-2 subcutaneous xenograft tumors were treated systemically with PBS or 4 × 10 10 vp/mice of ICOVIR15K or ICOVIR15K-iRGD. In A549 tumors, the enhanced virus dissemination observed at day 11 ( Figure 4 ) led to an improved antitumor efficacy of ICOVIR15K-iRGD showing statistically significant differences compared with the control group PBS from day 29 until the end of treatment, and from day 40 until the end of treatment compared with ICOVIR15K. ICOVIR15K-iRGD led to a threefold decrease in the tumor volume compared with PBS group at day 40 after virus administration, when PBS-treated animals were killed owing to their tumor volume (P = 0.014). A 1.68-fold decrease in the tumor volume was observed at the end of the treatment compared with ICOVIR15K (P = 0.036) (Figure 5a ). iRGD insertion in the ICOVIR15K fiber C terminus also led to a statistically significant improvement in the animal mean survival time: from 26 days for PBS-treated animals and 34 days for ICOVIR15K-treated animals to 46.4 days for ICOVIR15K-iRGDtreated animals (P = 0.01 compared with PBS and P = 0.018 compared with ICOVIR15K) (Figure 5b ). In MIA PaCa-2 tumors, ICOVIR15K showed almost no antitumor efficacy (only significant compared with PBS group from days 11 to 18 after virus administration). In contrast, ICOVIR15K-iRGD presented statistically significant antitumor activity compared with PBS group from day 6 after virus administration until the end of the experiment at day 48. Compared with ICOVIR15K, ICOVIR15K-iRGD resulted in a statistically significant better tumor growth control from the start of the experiment until day 21. ICOVIR15K-iRGD led to a 1.75-fold decrease in the tumor volume compared with PBS (P = 0.016) and 1.64-fold compared with ICOVIR15K (P = 0.046) (Figure 5c ). Mean survival increased from 17.7 days for the PBS group and 22.7 days for the ICOVIR15K group to 33.2 days for the ICOVIR15K-iRGD (P = 0.001 compared with PBS and P = 0.028 compared with ICOVIR15K) (Figure 5d ). iRGD-modified oncolytic adenovirus C Puig-Saus et al DISCUSSION One of the main barriers to virotherapy is the poor virus penetration into the tumor parenchyma. Seeking to improve it, we have inserted the iRGD tumor-penetrating peptide into the fiber C terminus of the oncolytic adenovirus ICOVIR15K. Although our in vitro characterization of the iRGD-modified oncolytic adenovirus did not reveal a clear advantage in transduction and cytotoxicity in tumor cells, the iRGD effect in vivo was most relevant. Of note, for many other peptides a clear in vitro tumor targeting advantage has failed to translate into in vivo tumor targeting. [26] [27] [28] We showed that NRP-1 binding through the insertion of the RPARPAR CendR NRP-1-binding prototype peptide in the fiber C terminus of ICOVIR15K enhanced binding and internalization of the virus in cell lines that express high and moderate levels of NRP-1. The same effect was achieved by the insertion of the iRGD peptide. However, to mediate its internalizing function, iRGD needs to bind to integrins and to be proteolytically processed by an unknown protease. The lack of effect of iRGD in A549 and HUVEC cells could be related to the absence of this putative protease or to the competition with the natural adenovirus primary receptors. Despite enhancing binding and internalization in vitro in MCF7 cells, iRGD insertion did not improve the transduction of a vector with the KKTK-to-RGDK fiber shaft modification. Moreover, although the RPARPAR peptide enhanced binding and internalization in A549 cells, it did not increase cytotoxicity of ICOVIR15K. These results seem to indicate that internalization of the virus through NRP-1 does not lead to the endocytic pathway to allow for virus nuclear transport, gene expression and replication. Importantly, the insertion of iRGD and RPARPAR peptides does not impair adenovirus natural entry pathway via receptor-mediated endocytosis through CAR and integrins, as transduction and cytotoxicity of modified viruses were the same as the control virus. In vivo, iRGD insertion in the fiber C terminus enhanced tumor transduction of a KKTK-to-RGDK-modified adenoviral vector, and ICOVIR15K early adenovirus dissemination and antitumor efficacy. The insertion of the iRGD peptide in the fiber C terminus slightly enhanced tumor transduction without altering the biodistribution of the AdGLK tumor-retargeted adenoviral vector. Although iRGD doubled the amount of transduced cells in MIA PaCa-2 tumors, liver and spleen were still the most efficiently transduced organs. Of note, iRGD peptide, contrary to RPARPAR peptide, did not increase significantly the transduction in other organs that could lead to enhanced toxicity. This lack of enhanced toxicity was confirmed by the absence of mice body weight loss compared with ICOVIR15K-treated mice in the antitumor efficacy experiments (data not shown). In MIA PaCa-2 cells, expressing low levels of NRP-1, no differences were observed in binding, internalization ( Figure 1c ) and cytotoxicity experiments (Figure 2c) between viruses with or without the iRGD or RPARPAR peptides. Moreover, internalization of the virus through NRP-1 did not enhance virusmediated gene expression. Based on these results, we hypothesized that the enhanced tumor transduction was associated with the interaction with the NRP-1 present in the tumor vasculature that caused an enhanced blood vessel extravasation and virus penetration through the tumor mass. To demonstrate this improved extravasation and penetration, we colocalized adenovirus and endothelial cells in tissue sections after administration of the adenoviral vectors AdGLK and AdGLK-iRGD. However, we could not detect either input virus capsid or GFP expression as the amount of virus that reached the tumor was low and it could only be detected by highly sensitive techniques such as luciferase quantification. To circumvent this technical limitation, and given the fact that the iRGD peptide did not enhance transduction and cytotoxicity of the virus in vitro (Figures 2a and b) , we considered the enhanced dissemination through the tumor mass at an early time point (day 11 after virus administration) as a good surrogate marker of enhanced penetration.
It is interesting to highlight that while the effect of iRGD in vitro was only observed in one cell line (MCF7), which expresses NRP-1 and α v β 5 and very low levels of CAR, in vivo it was observed in A549 and MIA PaCa-2 models, independently of NRP-1 levels, but not in MCF7 (not shown). It is likely that the absence of CAR in MCF7 contributed to better observe the effect of iRGD in binding and internalization in vitro. These in vivo results support the main role of the vasculature and stroma in the iRGD-mediated tumor penetration. iRGD could exert its function binding to NRP-1 present in tumor vessels. Tumor vasculature shares common antigens (such integrins and NRPs) regardless of the tumor type; 15, 29 consequently, a virus that targets these antigens may be suitable for a broad range of tumors. In this regard, we have assessed the expression of human and murine NRP-1 in different xenograft tumors and confirmed that murine NRP-1, representative of the vascular component of the tumor, is expressed in all tested tumors, while the expression of human NRP-1 from tumor cells is variable depending on the tumor origin (not shown). Moreover, it is conceivable that the protease that will expose the CendR motif of the iRGD could be expressed not only by tumor cells but also by the stromal cells of the tumor, explaining why iRGD-modified oncolytic adenovirus C Puig-Saus et al iRGD does not show its internalizing phenotype in vitro in the same models studied in vivo. 30, 31 Similar to tumor-penetrating peptides, cationic peptides such as the human immunodeficiency virus type 1 Tat protein transduction domain allow cell penetration through the interaction with the negative charges in the cell surface. This peptide has been inserted in adenovirus fiber C-terminus-enhancing tumor transduction, 32 and in the hexon hypervariable region-5-enhancing antitumor activity and survival. 33 However, this peptide does not exert tumor selectivity. 34 Other strategies seeking to improve adenovirus extravasation have been described, such as the expression of the Gibbon ape leukemia virus fusogenic membrane glycoprotein under the control of an endothelial specific promoter, which generates endothelial-epithelial fusions that create a new access route for the virus from the blood into the tumor parenchyma. 35 In addition, the pretreatment with tumor necrosis factor has been shown to increase vascular permeability, extravasation of the adenovirus into the tumors and transgene expression. 36 Our results show that iRGD inserted in the adenovirus capsid does not affect cell transduction and cytotoxicity of the virus, but enhances tumor transduction, early adenovirus dissemination through the tumor parenchyma and antitumor efficacy. Of note, the phenotype of iRGD is additive to the KKTK-to-RGDK fiber shaft modification that has been previously shown to enhance tumor transduction and antitumor activity. 11, 22 Despite the enhanced penetration, once inside the tumor iRGD-modified viruses also face stromal and extracellular matrix barriers. To further improve the oncolytic therapy outcome, strategies attacking the major barriers to adenovirus intratumoral dissemination should be combined. Altogether, our results show the relevance of iRGD insertion in the adenovirus capsid to improve the therapeutic effect not only of oncolytic adenoviruses but also of adenoviral gene therapy vectors.
MATERIALS AND METHODS

Cell lines
Human embryonic kidney 293, human lung adenocarcinoma A549 and human pancreas adenocarcinoma MIA PaCa-2 cell lines were cultured in Dulbecco's modified Eagle's medium (PAA, Les Mureaux, France) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA) and penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA). Human breast adenocarcinoma MCF7 cell line was cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin-streptomycin. HUVEC cells were maintained in Eagle's basal medium (Lonza, Basel, Switzerland) supplemented with endothelial cell growth EGM single quotes (human endothelial growth factor, hydrocortisone, gentamicin, bovine brain extract, fetal bovine serum, ascorbic acid) (Lonza), L-glutamine (Gibco), penicillin-streptomycin and up to 20% fetal bovine serum. All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines were routinely tested for the presence of mycoplasma.
Generation of recombinant adenoviruses and adenoviral vectors
All genetic modifications were performed following a recombineering protocol adapted from Stanton et al. 37 based on homologous recombination in bacteria and a positive-negative selection method with the RpsL-Neo selection cassette. To generate the pAdZ-ICOVIR15K-iRGD and pAdZ-ICOVIR15K-RPARPAR, a fragment containing the (GGGGS) 3 linker, the iRGD peptide (CRGDKGPDC) or the RPARPAR peptide, a stop codon and a polyadenylation site was inserted substituting the fiber stop codon in the pAdZ-ICOVIR15K plasmid carrying all genetic modifications of ICOVIR15K.
22 ICOVIR15K-RPARPAR was used as a control for NRP-1 binding without previous binding to integrins and proteolytic cleavage. To generate the pAdZGLK and pAdZGLK-iRGD, fragments containing the adenovirus fiber sequence with the RGDK modification and with or without the iRGD insertion in the C terminus were amplified by PCR from pAdZ-ICOVIR15K-iRGD and pAdTL-RGDK plasmids. 11 These PCR fragments were inserted in the pAdZGL (an adenoviral vector plasmid containing the GFP-luciferase fusion protein under the control of a cytomegalovirus promoter substituting adenovirus E1 region) substituting the fiber region.
All generated plasmids were transfected by calcium phosphate standard protocol into 293 cells to generate ICOVIR15K-iRGD, ICOVIR15K-RPARPAR, AdGLK and AdGLK-iRGD. Oncolytic viruses were plaque purified in A549 cells and further amplified and purified following a standard cesium chloride double-gradient protocol. Adenoviral vectors were further amplified in 293 cells and also purified following the standard cesium chloride double-gradient protocol. All plasmids and viruses were sequenced to confirm that they had all the indicated modifications. Cell extracts containing viruses were titered using an anti-hexon staining-based method obtaining the functional titer in TU/ml (transducing units per ml). Purified viruses were physically titered by optical density at 260 nm in terms of vp/ml. Infectious ratios (vp/TU) were similar among all purified tested viruses (49 vp/TU ratio for ICOVIR15K, 36.2 vp/TU ratio for ICOVIR15K-iRGD, 25.98 vp/TU for AdGLK and 33.24 vp/TU for AdGLK-iRGD). Purified viruses were titered by Taqman-based quantitative PCR method as described below for the binding and internalization experiments in terms of genomes per ml. All viral stocks were routinely tested for adenoassociated virus contamination.
Adenovirus-binding and internalization assay HUVEC and MCF7 cells (25 000 per well) and MIA PaCa-2 and A549 cells (50 000 per well) were seeded in 96-well plates. After 24 h, cells were infected with 10 000 genomes per cell of all indicated purified viruses diluted in cold media and incubated 90 min at 4°C in agitation. Then, cells were washed three times with cold PBS. For binding experiments, cells were lysed using 50 μl per well of lysis buffer (25 mM glycylglycine, 1% (v/v) Triton, 15 mM MgSO 4 , 4 mM EGTA, 1 mM DTT) for 2 min at 37°C. For internalization assays, after washing the cells, fresh media were added and cells were incubated for 60 min at 37°C to allow internalization. Finally, cells were washed three times with PBS, trypsinized and cell pellets lysed with 50 μl per pellet of lysis buffer. Cell extract samples were also collected to confirm that the amount of virus used was equal in all conditions.
Cell lysates for binding, internalization and standard curves were digested with proteinase K and SDS for 45 min at 54°C and for 10 min at 90°C to proteolyze the capsid and release the viral genomes. Adenovirus genomes were quantified by Taqman-based quantitative PCR method as described in Smith et al. 38 The two-tailed Student's t-test was used to compare the statistical significance of the differences in the amount of virus bound or internalized into the cell between viruses. In vitro cytotoxicity assay MIA Paca-2 (15 000 cells) and A549 (30 000 cells) were infected in suspension with serial dilutions (1/3 for MIA PaCa-2 cells and 1/5 for A549 cells) of the indicated viruses starting from 200 TU/cell. At day 5 postinfection (for MIA PaCa-2 cells) or at day 6 postinfection (for A549 cells), the total amount of protein content was quantified by bicinchoninic acid (Pierce Biotechnology, Rockford, IL, USA) and the IC 50 (half maximal inhibitory concentration) values were calculated by standard nonlinear regression (GraFit; Erithacus Software, Horley, UK) using an adapted Hill equation as described elsewhere. 39 The two-tailed Student's t-test was used to confirm that there were no statistically significant differences.
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Evaluation of in vivo biodistribution
In vivo studies were performed at the ICO-IDIBELL facility (Barcelona, Spain) AAALAC unit 1155, and approved by IDIBELL's Ethical Committee for Animal Experimentation. To evaluate AdGLK and AdGLK-iRGD biodistribution, 3 × 10 6 MIA PaCa-2 pancreatic adenocarcinoma cells were implanted subcutaneously in both flanks of 8-week-old female BALB/C nu/nu mice. At day 15 postimplantation, when the tumors reached 200 mm 3 approximately, mice were randomized and distributed into three groups (n = 6-8 animals/group). Mice were injected through the tail vein with PBS or 4 × 10 10 vp/mice of AdGLK or AdGLK-iRGD. Three days after virus administration, 250 μl of D-luciferin firefly potassium salt (15 mg/ml in PBS) were administered intraperitoneally and animals were killed after 15 min. Organs present in Figure 3 were collected and luciferase expression was quantified by an In Vivo Imaging System (IVIS, Lumina XR Real Time Bioluminiscence, Fluorescence and X-Ray Imaging System; Caliper Life Sciences-Perkin-Elmer, Waltham, MA, USA). The two-tailed Student's t-test was used to compare the statistical significance of transduction differences between groups.
Evaluation of antitumor efficacy in vivo
Lung adenocarcinoma or pancreatic adenocarcinoma xenograft tumors were established implanting 6 × 10 6 A549 cells or 10 × 10 6 MIA PaCa-2 cells subcutaneously into both flanks of 8-week-old female BAlb/C nu/nu mice. When A549 and MIA Paca-2 tumors reached 100-120 and 160-170 mm 3 , respectively, mice were randomized, distributed into three groups (n = 11-12 tumors/group) and treated systemically with a single dose of PBS or 4 × 10 10 vp/mice of ICOVIR15K or ICOVIR15K-iRGD injected through the tail vein. Twice a week, body weight and tumor size were measured with a digital caliper. Tumor volume was calculated according to the equation V (mm 3 ) = π/6 × W × L2, where W and L are the width and the length of the tumor, respectively. The two-tailed Student's t-test was used to study the statistical significance of the differences in the tumor volume of the different treatment groups. For Kaplan-Meier survival curves, end point was established at a tumor volume ⩾ 500 mm 3 . The animals whose tumor size never reached the threshold were included as right censored information. A log-rank test was used to determine the statistical significance of the differences in time-to-event.
Immunofluorescent detection of blood vessels and adenovirus E1A protein in xenograft tumors OCT-embedded sections of A549 tumors from animals treated systemically with PBS or 4 × 10 10 vp/mice of ICOVIR15K, ICOVIR15K-RPARPAR or ICOVIR15K-iRGD at day 11 after virus administration were used to detect E1A expression as described in Puig-Saus et al. 39 Representative images were obtained in a Nikon 80I Fluorescence microscope (Nikon, Tokyo, Japan). The E1A-positive area of these images was quantified with Volocity software (Perkin-Elmer). Two-tailed Student's t-test was used to assess the statistical significance between the mean E1A-positive area of ICOVIR15K and ICOVIR15K-iRGD treated tumors.
Formalin-fixed, paraffin-embedded sections of A549 tumors at day 11 after virus administration were used to double stain against α-SMA and E1A. Tissue sections were incubated overnight at 65°C, deparaffinized and rehydrated. Tissue sections were incubated in citrate buffer, blocked with 10% fetal bovine serum diluted in PBS-Triton 0.3% and incubated overnight at 4°C with anti-α-SMA mouse monoclonal (1A4) immunoglobulin G, Abcam7817 (Abcam, Cambridge, UK) and anti-adenovirus-2/5 E1A (13 S-5) SC-430 rabbit polyclonal immunoglobulin G (Santa Cruz Biotechnology, Dallas, TX, USA) primary antibodies. Slides were consequently incubated with Alexa Fluor 488-labeled goat anti-rabbit immunoglobulin G (Invitrogen Molecular Probes, Eugene, OR, USA) and Alexa Fluor 546-labeled goat anti-mouse immunoglobulin G (Invitrogen Molecular Probes) secondary antibodies. Finally, slides were counterstained with 4 0 ,6-diamidino-2-phenylindole. Representative mosaic images were obtained on an inverted fluorescence microscope Zeiss Axio observer Z1 with Zeiss Axio Cam MRm camera and with the EC 'Plan-Neofluar' 10 × NA 0.3 objectives (Zeiss, Oberkochen, Germany).
